NSCLC Stage IVPhase 2NCT06401824
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
A Phase 2 study testing Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab in people with NSCLC Stage IV and Brain Metastases, Adult, run by Maastricht University Medical Center at 3 sites in Netherlands.
Trial summary
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- NSCLC Stage IV, Brain Metastases, Adult
- What is being tested?
- Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 3 sitesNetherlands
- Study dates
- 24 Apr 2025to 1 Apr 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Participant is an adult ≥ 18 years of age at the time of informed consent.
- ECOG performance status ≤1.
- Estimated life expectancy of 12 weeks or more.
- Pathology proven metastatic non-squamous NSCLC
Show all 26Show fewer
- For those without an actionable oncogenic driver: progression on immunotherapy and/or platinum-doublet chemotherapy (concurrent or sequential, in any order). If contra-indication for immunotherapy: progression on platinum-doublet chemotherapy.
- For those with an actionable oncogenic driver: progression on targeted therapy and platinum-doublet chemotherapy. For the latter group, previous ICI is allowed but not mandatory.
- BM not in eloquent area (all patients have at least to be discussed with a neurologist, and preferably they are discussed in the local neuro-oncology MDT).
- Maximum BM size 2 cm in longest diameter (for each BM).
- At least one untreated brain metastasis ≥ 5mm:
- Patients with largest measurable intracranial lesion ≥5 mm but <10 mm may be allowed to enroll upon agreement with the principal investigator (for patients with target lesions of ≥ 5mm but <10 mm, 1.5 mm slice thickness brain MRI is required).
- Prior local treatment is permissible provided unequivocal progression in the lesion has since occurred (discussed in neuro-oncology MDT) or if new lesions have occurred.
- For at least 7 days prior to first dose of SG and bevacizumab in this study: Patient must be asymptomatic from CNS metastases and on a stable dose of corticosteroids, with a maximum of 4 mg dexamethasone/day. Anti-epileptic dose should also be stable for 7 days.
- Participant must have recovered from all toxicities related to prior treatments to grade ≤ 1 (CTCAE v 5.0). Exception to this criterion are alopecia and neuropathy of any grades.
- Adequate organ function including the following laboratory values at the screening visit:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (without growth factor support),
- Platelets ≥ 100 x 109/L (without growth factor support),
- Hemoglobin (Hb) ≥ 6 mmol/l (= 9 g/dl) (7 days without transfusions or growth factor support),
- Aspartate transaminase (AST) ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases
- Alanine transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases
- Serum albumin > 3 g/dL
- Total bilirubin ≤ 1.5 ULN,
- Creatinine clearance ≥ 30 mL/min by calculation using Cockcroft-Gault formula or based on 24-hour urine sample assessment.
- Participant is capable of following instructions regarding study treatment administration, and must be able to communicate with the Investigator and comply with the requirements of the study procedures.
- Negative serum or urine pregnancy test within 7 days prior to study treatment in women with childbearing potential. Patient must be willing to use effective methods of contraception. Female patients must be postmenopausal, surgically sterile, or they must agree to use a physical barrier method of contraception in addition to either an intrauterine device or hormonal contraception until at least 4 months after termination of study drug.
Who cannot join
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Leptomeningeal metastasis (based on MRI or CSF cytology, if strong suspicion despite negative MRI, CSF analysis should be done).
- Previous treatment with TROP2 inhibitor or angiogenesis inhibitor.
- Known hypersensitivity to the study drugs, its metabolites, or formulation excipient.
- Positive serum pregnancy test or women who are breastfeeding.
- Contra-indication for MRI.
Show all 43Show fewer
- History of allogeneic bone marrow or solid organ transplant.
- Have had a prior anticancer biologic agent (ADC, ICI) within 4 weeks prior to enrolment or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry.
- Note: Patients participating in observational studies are eligible.
- Have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs due to a previously administered agent.
- Note: patients with any grade vitiligo or alopecia are an exception to this criterion and will qualify for the study.
- Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Have an active second malignancy. Note: patients with a history of malignancy that has been treated completely, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumours with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll.
- Met any of the following criteria for cardiac disease:
- Myocardial infarction or unstable angina pectoris within 6 months of enrollment.
- History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.
- New York Heart Association (NYHA) class III or greater congestive heart failure or left ventricular ejection fraction of < 40%.
- Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrolment.
- Have active serious infection requiring antibiotics.
- Have known history of HIV-1 or 2 (or positive HIV-1/2 antibody, if done at screening) with detectable viral load OR taking medications that may interfere with SN-38 metabolism.
- Have known active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.
- Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
- Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the patient's participation in the study
- Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of first dose of study drug.
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary embolism within 1 months of enrolment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, uncontrolled pleural effusion, etc.); any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjogren syndrome, sarcoidosis, etc.); or prior pneumonectomy.
- Contra-indications specific to bevacizumab
- Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg). Anti-hypertensive therapy to achieve these parameters is allowable.
- Prior history of hypertensive crisis or hypertensive encephalopathy.
- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to start of treatment.
- History of hemoptysis (≥ one-half teaspoon of bright red blood per episode) within 1 month prior to start of treatment.
- Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
- Current or recent (within 10 days of start of treatment) use of aspirin (> 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol.
- Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for > 2 weeks prior to start of treatment. The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least 2 weeks prior to start of treatment.
- Prophylactic anticoagulation for the patency of venous access devices is allowed, provided the activity of the agent results in an INR < 1.5 × ULN and aPTT is within normal limits within 14 days prior to start of treatment.
- Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg/day) is permitted.
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab.
- History of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to start of treatment.
- Clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding.
- Evidence of abdominal free air not explained by paracentesis or recent surgical procedure.
- Serious, non-healing wound, active ulcer, or untreated bone fracture.
- Proteinuria, as demonstrated by urine dipstick or > 1.0 g of protein in a 24-hour urine collection. All patients with ≥ 2+ protein on dipstick urinalysis at baseline must undergo a 24-hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours.
- Clear tumour infiltration into the thoracic great vessels is seen on imaging.
- Clear cavitation of pulmonary lesions is seen on imaging.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands3 sites, 3 recruiting
- Recruiting
NKI-AvL
Amsterdam
W. Theelen, MD, PhD
- Recruiting
University Medical Center Groningen
Groningen
F. Bensch, MD, PhD
- Recruiting
Maastricht University Medical Center
Maastricht
L. Hendriks, MD, PhD, +31(0)43-3875047, lizza.hendriks@mumc.nl
L. Hendriks, MD, PhD
About this study
Official title: A Single Arm Phase II Study Evaluating Intracranial Efficacy of Sacituzumab Govitecan (SG) With Bevacizumab in Patients With Active, Asymptomatic Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Read the detailed description
Historically, the prognosis for patients with non-small cell lung cancer (NSCLC) brain metastases (BM) was poor, but this paradigm is slowly shifting as current data with an immune checkpoint inhibitor (ICI) based regimen show that a subgroup of patients with BM can achieve long-term survival. For patients with disease progression in the brain after platinum-doublet chemotherapy and ICI, no good systemic treatment options exist and due to local treatments, systemic therapy is often delayed. Of note, most of these patients also have extra-cranial disease progression which needs to be treated. The current standard of care post chemo-ICI progression is docetaxel, with dismal outcomes. The same holds true for patients with NSCLC with an actionable genomic alteration. Upon exhaustion of targeted therapies and platinum-doublet chemotherapy with or without ICI, the standard of care is docetaxel with the same dismal outcomes. Therefore, new systemic therapies that are active systemically as well as intracranially are needed in this population. Antibody-drug-conjugates (ADC) are promising new drugs and several have entered testing in randomized phase III trials. In the majority of the trials evaluating ADCs, patients with untreated BM were excluded. Importantly, Sacituzumab Govitecan (SG), a TROP2-ADC, achieves therapeutic concentrations of SN-38, the active payload of SG, in the CNS. SG is evaluated versus docetaxel in the ongoing EVOKE-1 trial (NCT05089734) but patients with untreated BM are excluded. Preclinically, SG combined with bevacizumab, but not with cetuximab, significantly improved survival over SG alone. Bevacizumab combined with chemotherapy results in an impressive intracranial ORR of 61%. Of note, a possible pseudo response (a marked decrease in contrast enhancement and oedema on MR imaging that often occurs after the initiation of bevacizumab therapy, attributed to normalization of the blood-brain barrier), was not taken into account. Pharmacokinetic drug-drug interactions between bevacizumab and SG are not expected given the distinct proteolytic catabolism responsible for degradation of each monoclonal antibody (moiety). In addition, SN-38 is metabolized by UGT1A1, which is not affected by bevacizumab. Based on the data above, it is of interest to also evaluate SG combined with bevacizumab in patients with BM from NSCLC. This will be evaluated in patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
- Conditions
- NSCLC Stage IV, Brain Metastases, Adult
- Being tested
- Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
- Keywords
- non small cell lung cancer, brain metastases, bevacizumab, sacituzumab govitecan
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sacituzumab Govitecan-Hziy 180 MG plus bevacizumabDrug
Also called sacituzumab govitecan; zirabev
Sacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.
| Study group | Role | What they receive |
|---|---|---|
| sacituzumab govitecan (SG) plus bevacizumab | Experimental | SG 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression. Receives: Drug: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
brain metastases overall response rate (ORR)
ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on central and local investigator's assessment according to RANO-BM criteria on brain MRI
Measured: up to 24 months
Secondary outcomes (8)
brain metastases overall response rate (ORR) with correction for bevacizumab-pseudoresponse
ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on central and local investigator's assessment according to RANO-BM criteria on brain MRI with additional criteria for potential pseudo response due to bevacizumab
Measured: up to 24 months
brain metastases disease control rate (DCR)
DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Non-CR/Non-PD according to RANO-BM on brain MRI
Measured: up to 24 months
CNS progression free survival (PFS)
PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on local and central assessment according to RANO-BM on brain MRI
Measured: up to 24 months
Extracranial ORR and DCR
ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on local investigator's assessment, DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Non-CR/Non-PD according to RECIST 1.1, measured with CT
Measured: up to 24 months
Extracranial PFS
PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on local assessment according to RECIST 1.1 based on CT
Measured: up to 24 months
overall PFS
median overall PFS based on RANO-BM for BM and RECIST 1.1 for extracranial lesions as defined above
Measured: up to 24 months
overall survival
OS is defined as the time from date of start of treatment to date of death due to any cause
Measured: up to 33 months
Safety according to CTCAE v5.0
according to CTCAE v5.0
Measured: up to 33 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2024
- Study start24 Apr 2025
- Primary completion1 Nov 2026 (estimated)
- Study completion1 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NSCLC Stage IVStudies of the same condition, open and under way.
- More trials run by Maastricht University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Maastricht University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Gilead Sciences
- Responsible party
- Sponsor
- Investigators
- Lizza Hendriks, MD, PhD, Principal investigator, Maastricht University Medical Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06401824
- Sponsor's protocol ID
- CO-NL-979-6888
- Status last verified
- May 2025
- First submitted
- 2 May 2024
- Last updated
- 6 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single Arm Phase II Study Evaluating Intracranial Efficacy of Sacituzumab Govitecan (SG) With Bevacizumab in Patients With Active, Asymptomatic Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- ClinicalTrials.gov ID
- NCT06401824
- Acronym / sponsor ID
- CO-NL-979-6888
- Conditions
- NSCLC Stage IV, Brain Metastases, Adult
- Keywords
- non small cell lung cancer, brain metastases, bevacizumab, sacituzumab govitecan
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Maastricht University Medical CenterUniversity, hospital or other
- Collaborators
- Gilead Sciences
- Study start
- 24 Apr 2025 (actual)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 1 Apr 2027 (estimated)
- First posted
- 7 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Detailed description
Historically, the prognosis for patients with non-small cell lung cancer (NSCLC) brain metastases (BM) was poor, but this paradigm is slowly shifting as current data with an immune checkpoint inhibitor (ICI) based regimen show that a subgroup of patients with BM can achieve long-term survival. For patients with disease progression in the brain after platinum-doublet chemotherapy and ICI, no good systemic treatment options exist and due to local treatments, systemic therapy is often delayed. Of note, most of these patients also have extra-cranial disease progression which needs to be treated. The current standard of care post chemo-ICI progression is docetaxel, with dismal outcomes. The same holds true for patients with NSCLC with an actionable genomic alteration. Upon exhaustion of targeted therapies and platinum-doublet chemotherapy with or without ICI, the standard of care is docetaxel with the same dismal outcomes. Therefore, new systemic therapies that are active systemically as well as intracranially are needed in this population. Antibody-drug-conjugates (ADC) are promising new drugs and several have entered testing in randomized phase III trials. In the majority of the trials evaluating ADCs, patients with untreated BM were excluded. Importantly, Sacituzumab Govitecan (SG), a TROP2-ADC, achieves therapeutic concentrations of SN-38, the active payload of SG, in the CNS. SG is evaluated versus docetaxel in the ongoing EVOKE-1 trial (NCT05089734) but patients with untreated BM are excluded. Preclinically, SG combined with bevacizumab, but not with cetuximab, significantly improved survival over SG alone. Bevacizumab combined with chemotherapy results in an impressive intracranial ORR of 61%. Of note, a possible pseudo response (a marked decrease in contrast enhancement and oedema on MR imaging that often occurs after the initiation of bevacizumab therapy, attributed to normalization of the blood-brain barrier), was not taken into account. Pharmacokinetic drug-drug interactions between bevacizumab and SG are not expected given the distinct proteolytic catabolism responsible for degradation of each monoclonal antibody (moiety). In addition, SN-38 is metabolized by UGT1A1, which is not affected by bevacizumab. Based on the data above, it is of interest to also evaluate SG combined with bevacizumab in patients with BM from NSCLC. This will be evaluated in patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| sacituzumab govitecan (SG) plus bevacizumab | Experimental | Drug: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumabSG 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (26 listed)
- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Key exclusion criteria (43 listed)
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sacituzumab Govitecan-Hziy 180 MG plus bevacizumabAlso: sacituzumab govitecan; zirabevSacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression. | Drug | sacituzumab govitecan (SG) plus bevacizumab |
Primary outcome
brain metastases overall response rate (ORR)
Time frame: up to 24 months
ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on central and local investigator's assessment according to RANO-BM criteria on brain MRI
8 secondary outcomes
brain metastases overall response rate (ORR) with correction for bevacizumab-pseudoresponse
Time frame: up to 24 months
brain metastases disease control rate (DCR)
Time frame: up to 24 months
CNS progression free survival (PFS)
Time frame: up to 24 months
Extracranial ORR and DCR
Time frame: up to 24 months
Extracranial PFS
Time frame: up to 24 months
overall PFS
Time frame: up to 24 months
overall survival
Time frame: up to 33 months
Safety according to CTCAE v5.0
Time frame: up to 33 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2025.
- Individual participant dataSharing planned: No
Related trials for NSCLC Stage IV
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
Active, not recruitingPhase 2
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lizza Hendriks, MD, PhD principal investigator
Maastricht University Medical Hospital
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab in people with NSCLC Stage IV and Brain Metastases, Adult, run by Maastricht University Medical Center at 3 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 26 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lizza Hendriks, MD, PhD (+31(0)43-3875047, lizza.hendriks@mumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
brain metastases overall response rate (ORR) (time frame: up to 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2025.